| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.087 | 0.6 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.6 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |